III. Meta-analysis of risedronate for the treatment of postmenopausal osteoporosis

Endocrine Reviews

Volumn 23, Issue 4, 2002, Pages 517-523

  Cranney, Ann ^a   Tugwell, Peter ^a   Adachi, Jonathan ^a   Weaver, Bruce ^a   Zytaruk, Nicole ^a   Papaioannou, Alexandra ^a   Robinson, Vivian ^a   Shea, Beverley ^a   Wells, George ^a   Guyatt, Gordon ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; RISEDRONIC ACID; VITAMIN D; DRUG DERIVATIVE; ETIDRONIC ACID;

BONE DENSITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HIGH RISK PATIENT; HUMAN; LUMBAR SPINE; MEDLINE; META ANALYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; RISK ASSESSMENT; VERTEBRA FRACTURE; FRACTURE;

ETIDRONIC ACID; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS;

EID: 0036678488     PISSN: 0163769X     EISSN: None     Source Type: Journal    
DOI: 10.1210/er.2001-3002     Document Type: Review

References (21)

1. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial
2. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis
3. The statistical basis of meta-analysis
4. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo controlled study
5. Bisphosphonates act directly on the osteoclast to induce caspase cleavage of mst1 kinase during apoptosis. A link between inhibition of the mevalonate pathway and regulation of an apoptosis-promoting kinase
6. Risedronate
7. Treatment of osteoporosis with bisphosphonates
8. Bisphosphonates in the treatment of disorders of mineral metabolism
9. Bisphosphonate therapy
10. The effects of risedronate plus estrogen compared with estrogen alone in postmenopausal women
11. Risedronate increases bone mineral density and is well-tolerated in postmenopausal women with low bone mineral density
12. Risedronate reduces hip fractures in patients with low femoral neck bone mineral density
13. Risedronate reduces vertebral fracture risk after the first year of treatment in postmenopausal women with established osteoporosis
14. A 2-year phase II study with 1 year of follow-up of risedronate (NE-58095) in postmenopausal osteoporosis
15. Effect of risedronate on the risk of hip fracture in elderly women
16. Risedronate reverses bone loss in postmenopausal women with low bone mass: Results from a multinational, double-blind, placebo-controlled trial
17. Risedronate increases bone mineral density at the hip, spine, and radius in postmenopausal women with low bone mass
18. Risedronate increases bone mass in an early postmenopausal population: Two years of treatment plus one year of follow-up
19. Risedronate prevents bone loss in early postmenopausal women
20. Therapy